- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01491373
Pilot Study of rhBMP-2/ACS/LT-CAGE® for Anterior Lumbar Interbody Fusion in Patients With Degenerative Disc Disease
August 1, 2013 updated by: Medtronic Spinal and Biologics
A Feasibility Investigation of Recombinant Human Bone Morphogenetic Protein-2 and Absorbable Collagen Sponge With LT-CAGE® Device for Anterior Lumbar Interbody Fusion in Patients With Degenerative Disc Disease
This study is designed to evaluate the feasibility of recombinant human bone morphogenetic protein-2 and absorbable collagen sponge with the tapered interbody fusion device (LT-CAGE® ) for anterior lumbar interbody fusion in patients with degenerative disc disease.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
14
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Has degenerative disc disease as noted by back pain of discogenic origin with degeneration of the disc confirmed by radiographic studies.
- Has no greater than Grade 1 spondylolisthesis utilizing Meyerding's Classification (Meyerding HW, 1932.)
- Has single level symptomatic degenerative involvement from L2 to S1.
- Is between the ages of 18 and 65, inclusive, at the time of surgery.
- Is willing to comply with the study plan and sign the Patient Informed Consent Form.
- Has not responded to conservative treatment for a period of 5 months.
- If of child-bearing potential, subject is non-pregnant (documented by a negative Pregnancy test within 72 hours of surgery), non-nursing female who agrees to use adequate contraception for 16 weeks following surgery
Exclusion Criteria:
- Has spinal condition other than symptomatic degenerative disc disease at the involved surgical level.
- Had previous anterior surgical procedures at the involved spinal level.
- Has a condition which requires postoperative medications that interfere with fusion such as steroids or nonsteroidal anti-inflammatory drugs. (This does not include low dose aspirin for prophylactic anticoagulation.)
- Has osteopenia, osteoporosis, or osteomalacia to a degree that spinal instrumentation would be contraindicated.
- Has circulatory problems, such as thrombophlebitis, lymphedema, or vascular deficiency at the implant site.
- Has symptomatic cardiac disease.
- Has presence of active malignancy or history of cancer in the past 5 years.
- Has overt or active infection.
- Is obese, i.e., weight greater than 40% over ideal for their age and height.
- Has fever (temperature > 101°F oral).
- Has local inflammatory signs indicative of infection.
- Has a documented metal allergy or intolerance.
- Is involved in a worker's compensation or unresolved spinal litigation case.
- Is mentally incompetent (either documented or in the opinion of the investigator).
- Has psychogenic magnification of pain (in the opinion of the investigator).
- Is a prisoner.
- Is pregnant.
- Is an alcohol and/or substance abuser.
- Requires bone growth stimulation in the lumbar spine.
- Is a tobacco user at the time of surgery.
- Patient has received drugs which may interfere with bone metabolism within two weeks prior to the planned date of spinal fusion surgery (e.g., steroids or methotrexate).
- Patient has a history of autoimmune disease (systemic lupus erythematosus or dermatomyositis).
- The subject has a history of exposure to injectable collagen implants.
- Patient's history includes hypersensitivity to protein pharmaceuticals (monoclonal antibodies or gamma globulins) or collagen.
- Patient has received treatment with an investigational therapy within 28 days prior to implantation surgery or such treatment is planned during the 16 weeks following rhBMP-2/ACS implantation.
- Patient has received any previous exposure to BMP.
- The patient requires allograft or bone substitute as part of treatment.
- Patient has history of endocrine or metabolic disorder known to affect osteogenesis (e.g. Paget's disease, renal osteodystrophy, Ehlers-Danlos syndrome, or osteogenesis imperfecta).
- Patient in the physician's opinion, would not be a good candidate for this surgical procedure.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: rhBMP-2/ACS
|
rhBMP-2/ACS inserted into Sofamor Danek's LT-CAGE® device.
Other Names:
|
Active Comparator: Autograft
|
LT-CAGE® device filled with autogenous bone taken from the patient's iliac crest
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Fusion
Time Frame: 24 month
|
24 month
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pain Assessment (Oswestry Disability Index, ODI)
Time Frame: 24 month
|
24 month
|
Neurological Status Assessment
Time Frame: 24 month
|
24 month
|
Health status assessment (SF-36)
Time Frame: 24 month
|
24 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 1997
Primary Completion (Actual)
September 1, 1999
Study Completion (Actual)
September 1, 1999
Study Registration Dates
First Submitted
December 12, 2011
First Submitted That Met QC Criteria
December 12, 2011
First Posted (Estimate)
December 14, 2011
Study Record Updates
Last Update Posted (Estimate)
August 2, 2013
Last Update Submitted That Met QC Criteria
August 1, 2013
Last Verified
December 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C-9504
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Degeneration of Lumbar Intervertebral Disc
-
Technical University of MunichCompleted
-
Zimmer BiometCompletedDegeneration of Lumbar Intervertebral DiscUnited States
-
Synthes USA HQ, Inc.CompletedDegeneration of Lumbar Intervertebral DiscUnited States
-
NuVasiveCompletedDegeneration of Lumbar Intervertebral DiscUnited States, Switzerland, Puerto Rico
-
Spineology, IncCompletedDegeneration of Lumbar Intervertebral DiscUnited States
-
Shanghai General Hospital, Shanghai Jiao Tong University...RecruitingLumbar Disc Herniation | Lumbar Disc DegenerationChina
-
R-BioKorea University Anam HospitalWithdrawnLumbar Intervertebral Disc DegenerationKorea, Republic of
-
DePuy SpineJanssen Korea, Ltd., KoreaCompletedEarly Lumbar Disc DegenerationKorea, Republic of
-
DePuy SpineJanssen-Cilag Pty LtdCompleted
-
Qiang Zhou, MD. PhD.Unknown
Clinical Trials on rhBMP-2/ACS/LT-CAGE® Device
-
Medtronic Spinal and BiologicsCompleted
-
Medtronic Spinal and BiologicsCompleted
-
University of Alabama at BirminghamNot yet recruitingBone LossUnited States
-
Medtronic Spinal and BiologicsCompleted
-
Medtronic Spinal and BiologicsTerminatedLumbar Spine DegenerationUnited States
-
Medtronic Spinal and BiologicsTerminated
-
Medtronic Spinal and BiologicsCompleted
-
Medtronic Spinal and BiologicsTerminated
-
Medtronic Spinal and BiologicsCompleted
-
Lindenhofgruppe AGRecruitingDegenerative Disc Disease | Spondylosis | SpondylolisthesisSwitzerland